Xenon Pharmaceuticals Inc (XENE):企業の財務・戦略的SWOT分析

【英語タイトル】Xenon Pharmaceuticals Inc (XENE) - Financial and Strategic SWOT Analysis Review

GlobalDataが出版した調査資料(GDPH132674FSA)・商品コード:GDPH132674FSA
・発行会社(調査会社):GlobalData
・発行日:2021年4月
・ページ数:25
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Xenon Pharmaceuticals Inc (Xenon), formerly Xenon Genetics Inc, is a biopharmaceutical company that develops medicines to treat neurological disorders. The company is investigating XEN1101, a Kv7 potassium channel modulator against epilepsy; XEN496 for the treatment of seizures associated with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). It is also evaluating XEN007, a CNS-acting calcium channel modulator targeting treatment-resistant childhood absence epilepsy (CAE); and FX-301 to treat post-operative pain. The company partners with Genentech, Flexion Therapeutics Inc and Neurocrine Biosciences Inc to develop and commercialize therapies. Xenon is headquartered in Burnaby, British Columbia, Canada.

Xenon Pharmaceuticals Inc Key Recent Developments

Mar 08,2021: Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101 for the Treatment of Major Depressive Disorder (MDD)
Feb 23,2021: Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2020 Financial Results
Jan 14,2021: Xenon Pharmaceuticals outlines key milestone opportunities and planned leadership transition in 2021
Nov 05,2020: Xenon Pharmaceuticals reports third quarter 2020 financial results and provides corporate update
Aug 17,2020: Xenon Pharmaceuticals appoints Dr. Chris Von Seggern as chief commercial officer

This comprehensive SWOT profile of Xenon Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Xenon Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Xenon Pharmaceuticals Inc – Key Information
Xenon Pharmaceuticals Inc – Overview
Xenon Pharmaceuticals Inc – Key Employees
Xenon Pharmaceuticals Inc – Key Employee Biographies
Xenon Pharmaceuticals Inc – Key Operational Heads
Xenon Pharmaceuticals Inc – Major Products and Services
Xenon Pharmaceuticals Inc – History
Xenon Pharmaceuticals Inc – Company Statement
Xenon Pharmaceuticals Inc – Locations And Subsidiaries
Xenon Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Xenon Pharmaceuticals Inc – Business Description
Xenon Pharmaceuticals Inc – Corporate Strategy
Xenon Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Xenon Pharmaceuticals Inc – Strengths
Xenon Pharmaceuticals Inc – Weaknesses
Xenon Pharmaceuticals Inc – Opportunities
Xenon Pharmaceuticals Inc – Threats
Xenon Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Xenon Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Xenon Pharmaceuticals Inc, Key Information
Xenon Pharmaceuticals Inc, Key Ratios
Xenon Pharmaceuticals Inc, Share Data
Xenon Pharmaceuticals Inc, Major Products and Services
Xenon Pharmaceuticals Inc, History
Xenon Pharmaceuticals Inc, Key Employees
Xenon Pharmaceuticals Inc, Key Employee Biographies
Xenon Pharmaceuticals Inc, Key Operational Heads
Xenon Pharmaceuticals Inc, Other Locations
Xenon Pharmaceuticals Inc, Subsidiaries
Xenon Pharmaceuticals Inc, Key Competitors
Xenon Pharmaceuticals Inc, SWOT Analysis
Xenon Pharmaceuticals Inc, Ratios based on current share price
Xenon Pharmaceuticals Inc, Annual Ratios
Xenon Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★調査レポート[Xenon Pharmaceuticals Inc (XENE):企業の財務・戦略的SWOT分析] (コード:GDPH132674FSA)販売に関する免責事項を必ずご確認ください。
★調査レポート[Xenon Pharmaceuticals Inc (XENE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆